Search

everythinglearnresearchcommunity

for

Search:↓

Male pattern baldness (MPB) may be influenced by androgen receptors in scalp hair follicles and potentially poor blood flow. Transplanted hair is not immune to DHT, and factors like inflammation and scalp tension might also contribute to hair loss.

The conversation discusses the effectiveness of official and gray market Pyrilutamide for hair loss. One user experienced chest pain with the gray market version, while another found the official Koshine version mildly effective.

The conversation is about comparing the effectiveness of fluridil and clascoterone in preventing hair loss and inquiring about their use as standalone treatments. There is a question about the concentration of the fluridil brand for efficacy.

Ketoconazole can slightly improve hair density and is best used as an adjunct to treatments like finasteride and minoxidil. It helps with scalp health but won't stop androgenetic alopecia on its own.

Pyrilutamide (KX-826) is being discussed as a potential hair loss treatment, with some users reporting no regrowth after three months. It may prevent further hair loss but might not promote regrowth unless combined with Minoxidil.

The conversation discusses various hair loss treatments, including minoxidil, finasteride, dutasteride, pyrilutamide, alfatrodial, and nizoral, with a focus on the potential of new treatments like gt20029 and breezula. There is optimism about novel treatments that don't have systemic effects, although skepticism remains about the effectiveness of some new drugs.

RU58841 was ineffective for OP, who is considering adding KX-826 with finasteride. User8 suggests KX-826 may help when combined with minoxidil and dutasteride.

Hair loss treatments Cosmerna, RU, and Pyri discussed. Cosmerna inhibits androgen receptors, but not 100%, so RU/Pyri can be used synergistically.

AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.

Hair loss discussion includes Minoxidil, Finasteride, and RU58841 treatments. Pyrilutamide cleared for phase 3 clinical trial in China.

PP405 is expected to finish Phase 2 trials in late 2025, with potential market availability around 2028-2029 if all goes well. Current treatments like finasteride and minoxidil are still popular, while new options like KX-826 and Breezula are anticipated soon.

A user's experience with the hair loss treatment Pyrilutamide KX-826, which has resulted in some side effects and shedding. The conversation also includes advice for baseline pictures and trying treatments for at least 6 months.

PP405 is likely a scam, with concerns about its legitimacy and safety, as it may cause unintended tissue growth. Users suggest sticking to known treatments like finasteride and minoxidil.

PP405 is considered a promising potential cure for hair loss, with phase 2 trial results expected in February 2025. Hair cloning is also discussed as a potential ultimate solution, despite significant scientific challenges.

The user is considering switching from finasteride to RU-58841 for hair loss due to side effects and is concerned about its safety around cats. They are also seeking dosage suggestions and alternatives like pyrilutamide.

A 30-year-old female with PCOS and male pattern baldness is frustrated with her endocrinologist's recommendation of only Spironolactone and minoxidil, feeling that dutasteride, finasteride, and progesterone would be more effective. Other users suggest various online sources for treatments, warn against self-medicating due to potential risks, and recommend seeking a specialized endocrinologist or considering additional treatments like Inositol, Berberine, and dermaneedling.

PP405 is viewed skeptically, with some seeing it as overhyped and potentially ineffective compared to existing treatments like minoxidil and finasteride. While it shows some promise in activating dormant hair follicles, many believe it won't replace hair transplants or significantly outperform current options.

PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hair follicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.

User experienced hair loss since 16, used Fin, Minox, and Nizoral with success but stopped due to side effects. Now using Pur D'or shampoo, Rogaine foam, scalp massages, volumizing spray, and dermarolling for hair maintenance.

PP405 is suspected to be a scam, with users doubting its legitimacy and effectiveness. Many recommend using proven treatments like finasteride and minoxidil.

The effects of Pyrilutamide, a hair loss treatment that is being tested for June/July; and reports from people who have experienced side effects similar to those of RU58841, suggesting they may have been sold an incorrect product from their supplier.

CB 03 01 (Breezula) was tried for hair loss but showed no significant improvement, with issues in dissolving and application. Finasteride and dutasteride remain the most effective treatments, while minoxidil is also used; CB's effectiveness is questioned, and topical alternatives like bicalutamide are considered.

The group buy for CB-03-01, a topical anti-androgen for hair loss, was postponed and refunded due to issues with the product's form and solubility. The product, also known as Breezula, is an alternative to finasteride with fewer side effects, but its official release is delayed until 2021.

The user is experiencing diffuse thinning and inflammation despite using 2.5mg dutasteride daily, ciclopirox, and ketoconazole shampoos. They are considering treatments like hydroxychloroquine and JAK inhibitors due to suspected scarring alopecia and have faced challenges in obtaining a scalp biopsy.

Verteporfin and BPC-157 are being discussed as potential treatments for hair loss. The conversation also mentions Minoxidil, finasteride, and RU58841.

A 17-year-old is looking for alternatives to finasteride for DHT control to preserve hair, considering ketoconazole shampoo for its potential to inhibit 5AR and also thinking about using caffeine-containing shampoos like alpecin or watermans.

The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. The user inquires if RENU Biogen is a DHT inhibitor.

The user applied Kindor's KU, followed by a solution of Finasteride, Minoxidil, and Tretinoin for alopecia. They experienced no side effects from Kindor's KU.

Kintor Pharma has finished enrolling the first patient in a Phase III trial for KX-826, a treatment for androgenetic alopecia (AGA). One user has set a reminder to check back on the topic in a year.

RU58841 caused severe side effects like heart palpitations and shortness of breath, leading the user to stop using it. Minoxidil and finasteride were effective without side effects, while RU58841's safety and effectiveness remain uncertain.